* Submits Japan regulatory application for mepolizumab in severe eosinophilic asthma
LONDON, May 11 (Reuters) - Britain's GlaxoSmithKline , which decided last week to retain rather than float off its HIV drugs business, is to collaborate with U.S. scientists in developing a cure for AIDS.
LONDON, May 7 (Reuters) - GlaxoSmithKline's new chairman Philip Hampton has thrown his support behind the company's current structure and chief executive despite pressure from some shareholders for a...
LONDON, May 7 (Reuters) - GlaxoSmithKline's new chairman Philip Hampton expressed support for the company's current structure and its chief executive on Thursday while speaking to reporters after the drugmaker's annual meeting.
* Manvinder Singh (Vindi) Banga will join board of company as a non-executive director on 1 September, 2015
LONDON, May 6 (Reuters) - After relying for years on its top-selling lung drug Advair, GlaxoSmithKline is now braced for the worst in the form of cheap generics - but not just yet.
* Q1 revenue 5.62 billion pounds, in line with consensus (Adds reaction and context)
Following Glaxo’s in-line first quarter and better-than-expected long-term guidance, we are holding firm to our fair value estimate of $47/GBX 1,510 (ADR/local). At current market prices, the stock looks fairly valued and carries a high but shaky dividend yield. We continue to support the company’s
LONDON, May 5 (Reuters) - GlaxoSmithKline said on Tuesday it had submitted a gene therapy for approval in Europe, becoming the first big drugmaker to seek marketing authorisation for the technology to fix faulty genes.
* Announce EU regulatory submission for gene therapy to treat rare disease ADA-SCID